Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Sickle Cell Disease
 More »

  • Is This Gene Therapy's Breakout Moment?
    bio secured a $60 million Series D financing round to advance clinical programs in childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia and sickle cell disease. ...
    4-1-2013
  • Development and Evolution of PCR
    ... DNA of a β-globin fragment containing the codon 6 mutated in sickle cell anemia (SCA). ... as well as disease association studies, has been replaced by PCR-based typing. ...
    4-1-2013
  • Is This Gene Therapy's Breakout Moment?
    bio secured a $60 million series D financing round to advance clinical programs in childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia, and sickle cell disease. ...
    3-4-2013
  • Top 10 VC & Biopharma Equity Deals of 2012
    ... investors 4 Purpose: Advance clinical programs in severe genetic disorders including childhood cerebral adrenoleukodystrophy (CCALD), beta-thalassemia and sickle cell disease. ...
    2-8-2013
  • Sickle Cells Can Cut Off Tumors' Lifeline
    Sickle cell disease is a lethal disorder in which misshapen red blood cells can clog blood vessels and cut of blood flow to organs. However, new research shows that this normally ...
    1-10-2013
  • The New Economics of Orphan Diseases
    ... Meekings says, "in terms of innovation, there are a large number of players trying new things." Sickle cell disease is a good example. With only one FDA-approved drug available, ...
    1-1-2013
  • Novel Applications for Systems Biology
    ... Sometimes this is clear, as in sickle-cell anemia, for example, but determining causality is ... Harvard Medical School, studies gene-disease associations to find evidence of ...
    12-1-2012
  • Bluebird Wins $9.3M for Beta-Thalassemia Gene Therapy
    Phase I/II trials of the product in the treatment of β-thalassemia and sickle cell disease are ongoing. Promising initial data were reported back in 2010, and showed that a single ...
    10-26-2012
  • Blood Flow as Diagnostic Marker
    Jamming, or vaso-occlusion, could be used to distinguish sickle cell disease patients with poor outcomes from those with good outcomes. ASSAY & Drug Development Technologies offers ...
    8-6-2012
  • Patheon, Adventrx Ink Manufacturing Pact for Cardiovascular Candidate
    finish of the latter's lead candidate ANX-188 (purified poloxamer 188) for clinical trials, including a Phase III study projected to start this year against sickle cell disease. ...
    6-26-2012
  • Third Rock Ventures Sets Up New Firm Global Blood Therapeutics...
    Global Blood Therapeutics' lead program focuses on sickle cell disease (SCD). It is caused by a point mutation in the hemoglobin beta chain, converting β6 glutamic acid to valine. ...
    6-14-2012
  • Gamida Cell Raises $10M to Progress Phase III-Stage Hematologic...
    of additional pipeline candidates, including clinical development of its cord blood-based NiCord® cell therapy for the treatment of sickle cell disease and thalassemia. ...
    5-15-2012
  • Gene Therapy Briefs
    ... Researchers from the U.S., Israel, and Italy have developed a gene therapy strategy that could feasibly treat both β-thalassemia and sickle cell disease, based on delivery of a ...
    5-1-2012
  • Gene Therapy Shows Promise for Treating Beta-Thalassemia and...
    Scientists have developed a gene therapy strategy that could feasibly treat both β-thalassemia and sickle cell disease. The technology is based on delivery of a lentiviral vector ...
    3-28-2012
  • HemaQuest Raises $13M to Fund Phase II Study with Sickle Cell...
    The firm will use the funds to carry out a Phase IIb study evaluating its lead short chain fatty acid derivative (SCFAD) compound HQK-1001 in patients with sickle cell disease. ...
    3-12-2012
  • More »

    Journal Articles

  • Consecutive Concomitant Laparoscopic Splenectomy and Cholecystectomy...
    Cinzia Nobili, Fabrizio Romano, Arianna Libera Ciravegna, Mattia Garancini, Luca Degrate, Fabio Uggeri, Franco Uggeri
    Journal of Laparoendoscopic& Advanced Surgical Techniquesand Part B, Videoscopy
    Indications were hereditary spherocytosis for 22 cases, idiopatic thrombocytopenic purpura for 3 cases, thalassemia for 4 cases, and sickle cell disease for 1 case. Patients were ...
  • RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease
    Angela D. Burnette, Shahid M. Nimjee, Milena Batchvarova, Rahima Zennadi, Marilyn J. Telen, Jun-ichi Nishimura, Bruce A. Sullenger
    Nucleic Acid Therapeutics
    RNA Aptamer Therapy for Vaso-Occlusion in Sickle Cell Disease Nucleic Acid Therapeutics Patients with sickle cell disease (SCD) often suffer painful vaso-occlusive episodes caused ...
  • Gender Differences in Pain and Healthcare Utilization for Adult...
    Donna K. McClish, James L. Levenson, Lynne T. Penberthy, Susan D. Roseff, Viktor E. Bovbjerg, John D. Roberts, Imoigele P. Aisiku, Wally R. Smith
    Journal of Women's Health
    Gender Differences in Pain and Healthcare Utilization for Adult Sickle Cell Patients: The ... People with sickle cell disease (SCD) experience both chronic and acute pain throughout ...
  • Cytokine Levels and Profiles in Children Related to Sickle Cell...
    Jennifer Knight-Madden, Diego Vergani, Richard Patey, Karl Sylvester, Munther J. Hussain, Terrence Forrester, Anne Greenough
    Journal of Interferon & Cytokine Research
    Cytokine Levels and Profiles in Children Related to Sickle Cell Disease and Asthma Status Journal of Interferon & Cytokine Research Atopic asthma in patients with sickle cell ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll